Fianlimab

Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity[1].

Product Specifications

CAS Number

[2126132-98-5]

Product Name Alternative

REGN3767

UNSPSC

12352203

Target

LAG-3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/fianlimab.html

Purity

99.04

Solubility

10 mM in DMSO

Smiles

[Fianlimab]

Molecular Weight

(146.46 kDa)

References & Citations

[1]Omid Hamid, et al. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.Meeting Abstract | 2021 ASCO Annual Meeting I.|[2]Burova E, et al., Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18 (11) :2051-2062.